Sponsor:
Mayo Clinic
Code:
NCT05518903
Conditions
Localized Pancreatic Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma
Stage 0 Pancreatic Cancer AJCC v8
Stage I Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Computed Tomography
Gallium Ga 68 FAPi-46
Positron Emission Tomography
Brief summary:
Conditions
Localized Pancreatic Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma
Stage 0 Pancreatic Cancer AJCC v8
Stage I Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8
Study ID
NCT05518903
Start date
Nov 15, 2022
Status verified date
Aug, 2026
Completion date
Jun 30, 2028
Anticipated
Primary completion date
Jun 30, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
130 participants
Anticipated
Intervention Model
Single group
Primary purpose
Diagnostic
Arms
experimental: Diagnostic (gallium GA 68 FAPi-46, PET/CT)
Interventions
Computed Tomography
Gallium Ga 68 FAPi-46
Positron Emission Tomography
Primary outcome measure
Locations
Mayo Clinic in Rochester
Recruiting
Rochester, Minnesota, United States, 55905
Contacts
Principal Investigator:
Ajit H. Goenka, M.D.
Sponsor
Mayo Clinic
Last update posted
Aug 10, 2026
Last verified
Aug, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-08-10.